biostudies-literatureHovakimyan AU.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and StrokeNIA NIH HHSU.S. Department of Health & Human Services | NIH | National Institute on AgingU.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)117https://www.ebi.ac.uk/biostudies/studies/S-EPMC9556597biostudies-literatureUnknown7(1)Pathological forms of Tau protein are directly associated with neurodegeneration and correlate with Alzheimer's Disease (AD) symptoms, progression, and severity. Previously, using various mouse models of Tauopathies and AD, we have demonstrated the immunogenicity and efficacy of the MultiTEP-based adjuvanted vaccine targeting the phosphatase activating domain (PAD) of Tau, AV-1980R/A. Here, we analyzed its immunogenicity in non-human primates (NHP), the closest phylogenic relatives to humans with a similar immune system, to initiate the transition of this vaccine into clinical trials. We have demonstrated that AV-1980R/A is highly immunogenic in these NHPs, activating a broad but unique to each monkey repertoire of MultiTEP-specific T helper (Th) cells that, in turn, activate B cells speciNPJ vaccinesImmunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates.PMC9556597U01 AG060965R01 AG-20241AG060965NS50895AG20241R01 NS-50895Ghochikyan AHovakimyan AAntonyan TZagorski KPetrovsky NChailyan GPetrushina IFoose CMelikyan LAgadjanyan MGKing OGhazaryan MCribbs DHBatt DGDonthi AfalseImmunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates.Pathological forms of Tau protein are directly associated with neurodegeneration and correlate with Alzheimer's Disease (AD) symptoms, progression, and severity. Previously, using various mouse models of Tauopathies and AD, we have demonstrated the immunogenicity and efficacy of the MultiTEP-based adjuvanted vaccine targeting the phosphatase activating domain (PAD) of Tau, AV-1980R/A. Here, we analyzed its immunogenicity in non-human primates (NHP), the closest phylogenic relatives to humans with a similar immune system, to initiate the transition of this vaccine into clinical trials. We have demonstrated that AV-1980R/A is highly immunogenic in these NHPs, activating a broad but unique to each monkey repertoire of MultiTEP-specific T helper (Th) cells that, in turn, activate B cells speci2022-01-01T00:00:00Z2022 Oct2025-04-22T02:13:54.74Z2025-04-05T20:21:37.494ZS-EPMC95565973622419110.1038/s41541-022-00544-3